Reversing anticoagulation: the latest results from the RE-VERSE AD trial Join Dr Charles Pollack for a discussion of his cutting-edge study: Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. Latest update Time required CPD credits Expiration date 15/09/2017 30 minutes Awaiting CPD accreditation 28/06/2018 Target audience This educational activity is designed for cardiologists, surgeons, primary care physicians, GPs, nurses and any other healthcare professional with an interest or role in atrial fibrillation management. Learning objectives After completing this activity, participants should:Describe how idarucizumab reverses the anticoagulation effects of dabigatran Faculty disclosures Dr Charles Pollack Thomas Jefferson University Hospital Philadelphia, USA Research support from: Boehringer Ingelheim, Janssen Pharma, Portola, Daiichi Sankyo, CSL BehringConsultant for (non promotional): Boehringer Ingelheim, Janssen Pharma, BMS/Pfizer, Portola, Daiichi Sankyo, CSL Behring Professor John Camm St George's University of LondonLondon, UK Advisor for: Boehringer Ingelheim, Daiichi SankyoConsultant (retained) for: Boehringer IngelheimReceived honoraria from: Bayer, Daiichi Sankyo, BMS-Pfizer Staff and reviewer disclosures ACHL staff, PCM Scientific staff, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. Financial support This independent educational activity is supported by funding from Boehringer Ingelheim. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme.The activity is run at arm’s length from the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.